Drugs / VRELysin™
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05715619 Comparator | Oct 2023 → Oct 2026 | — | Intralytix, Inc. | Suspended | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-12 | Intralytix, Inc. | Intralytix Launches Phase 1/2a Phage Therapy Trial of Its VRELysin™ Phage Preparation, to Assess Safety and Efficacy in Healthy and VRE-Colonized Subjects intralytix.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRELysin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05715619 ↗ |
| Modality | Other / unclassified | “VRELysin is a collection of bacteriophages.” NCT05715619 ↗ |
| Route | Oral | “A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution” NCT05715619 ↗ |